ChemLex runs a 24/7 autonomous chemistry system that pairs AI-driven molecular design with an automated synthesis line, aiming to speed up chemical and drug discovery for pharmaceutical companies. The company says it supports more than 70 customers worldwide, including six of the world's top ten pharmaceutical companies. ChemLex was founded in 2022 and named Singapore its global headquarters alongside its funding announcement, per the Singapore Economic Development Board and TNGlobal.
Builder’s Brief
ChemLex is a research tool on Falcoscan. Self-driving lab that accelerates AI-powered drug discovery. Falcoscan rates ChemLex with an Opportunity score of 78/100, a Saturation score of 14/100, and a Wrapper-risk score of 15/100. Market signal: rising. ChemLex is founded in 2022, currently at Series_a stage. Pricing: Paid.
Market position · Research
How ChemLex compares in Research
ChemLex's opportunity score of 78 ranks #20 of 87 live Research tools on Falcoscan, 2.4 points above the category average of 75.6. Its saturation score is 14/100, against a category average of 14.3. 33 of the 87 live Research tools carry a hot signal, and Falcoscan has recorded 14 shutdowns in the category.
The top-rated live Research tools on Falcoscan, other than ChemLex, are Altos Labs Bio AI, Biorender Scientific AI, Open Alex Research API, Anthropic Constitutional AI, and Undermind Research.
Is ChemLex still operating?
Yes. Falcoscan's operating checks list ChemLex as active.
Where is ChemLex based?
ChemLex is headquartered in Singapore.
Does ChemLex have an API?
Falcoscan's records show no public API for ChemLex.
Who is ChemLex for?
ChemLex is built for pharmaceutical companies and biotech researchers.